TGFB1 and renal fibrosis: Several basic and clinical studies have demonstrated that treatment with GLP-1 analogs or GLP-1R agonists greatly mitigates renal fibrosis associated with DN by inhibiting TGF-β1-activated Smad 3 and ERK1/2 [39].